Full Press Release Details
OS Therapies Clarifies
CUSIP of Common Stock
New York, NY, August 22, 2024
OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage
biopharmaceutical company, today provided a clarification for market participants, specifically brokerage firms, regarding the Committee
on Uniform Securities Identification Procedures (CUSIP) identifier of the Company's common stock.
The Company's common stock began trading
on the NYSE American on August 1st, 2024 under CUSIP 68764Y108 ("Old CUSIP"). On August 5th, the Company
completed certain matters related to a corporate action that had occurred prior to the listing of the Company's common stock on
the NYSE American that resulted in new CUSIP 68764Y207 ("New CUSIP") being assigned to the Company's common stock. All
shares sold or purchased under the Old CUSIP are now identified as the same number of shares under the New CUSIP. No share splits or any
other similar actions occurred between August 1, 2024 and August 5, 2024.
All market participants, including brokerage
firms, are hereby notified to update their records such that shares of the Company's common stock listed under the Old CUSIP should
be identified, sold and purchased under the New CUSIP 68764Y207.
OS Therapies is a clinical stage oncology
company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2,
the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong
immune response targeting the HER2 protein. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2
in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study
primarily in breast cancer patients, in addition to showing strong preclinical efficacy data in various models of breast cancer. In addition,
OS Therapies is advancing its next generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which
features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone linker
technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Corporate and Media Contact:
RedChip Companies, Inc.